HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen G Nuara Selected Research

Parkinsonian Disorders (Parkinsonism)

10/2023The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
10/2023Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
7/2023The 5-HT2A/2C inverse agonist nelotanserin alleviates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset.
1/2023Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset.
8/2022Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset.
12/2021Additive effects of mGluR2 positive allosteric modulation, mGluR2 orthosteric stimulation and 5-HT2AR antagonism on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset.
11/2021Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
1/2021Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset.
1/2021Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
11/2020Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen G Nuara Research Topics

Disease

22Psychotic Disorders (Schizoaffective Disorder)
10/2023 - 03/2017
21Dyskinesias (Dyskinesia)
10/2023 - 03/2017
17Parkinson Disease (Parkinson's Disease)
10/2023 - 01/2018
15Parkinsonian Disorders (Parkinsonism)
10/2023 - 01/2018
2Schizophrenia (Dementia Praecox)
10/2023 - 09/2018
1Drug-Induced Dyskinesia (Dyskinesia, Drug Induced)
07/2023
1Dementia (Dementias)
07/2023
1Mental Disorders (Mental Disorder)
09/2018

Drug/Important Bio-Agent (IBA)

22Levodopa (L Dopa)FDA LinkGeneric
10/2023 - 03/2017
201- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
10/2023 - 03/2017
9Serotonin (5 Hydroxytryptamine)IBA
07/2023 - 01/2018
5Glutamic Acid (Glutamate)FDA Link
10/2023 - 09/2018
4metabotropic glutamate receptor 2IBA
10/2023 - 09/2018
3Dopamine (Intropin)FDA LinkGeneric
10/2023 - 11/2020
35-HT2A Serotonin Receptor (5 HT2A Receptor)IBA
02/2019 - 03/2017
2Serotonin 5-HT2 Receptor AntagonistsIBA
08/2022 - 01/2018
2Therapeutic UsesIBA
11/2021 - 01/2021
2Monoamine Oxidase (MAO)IBA
11/2020 - 11/2020
2Moclobemide (Arima)IBA
11/2020 - 11/2020
1ProdrugsIBA
10/2023
1LY 2140023IBA
10/2023
1nelotanserinIBA
07/2023
1LY 341495IBA
08/2022
1N- (4- (2- methoxyphenoxy)phenyl)- N- (2,2,2- trifluoroethylsulfonyl)pyrid- 3- ylmethylamineIBA
08/2022
1eglumetadIBA
08/2022
1alpha-SynucleinIBA
01/2022
1(R)- (N- (3- (4'- fluorophenyl)- 3- (4'- phenylphenoxy)propyl))sarcosineIBA
11/2021
1Glycine Plasma Membrane Transport ProteinsIBA
11/2021
1Glycine (Aminoacetic Acid)FDA LinkGeneric
11/2021
1Ondansetron (Zofran)FDA LinkGeneric
01/2021
1Granisetron (Kytril)FDA LinkGeneric
01/2021
15-HT3 Serotonin Receptors (5 HT3 Receptor)IBA
01/2021
1EnzymesIBA
11/2020
1Oxidopamine (6 Hydroxydopamine)IBA
11/2019
1nefazodone (Serzone)FDA LinkGeneric
12/2018
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2018
1MianserinIBA
01/2018
1Trazodone (Trittico)FDA LinkGeneric
01/2018
1Clozapine (Clozaril)FDA LinkGeneric
03/2017
1Mirtazapine (Rexer)FDA LinkGeneric
03/2017
1pimavanserinIBA
03/2017

Therapy/Procedure

4Therapeutics
11/2021 - 09/2018